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INTRODUCTION 
Haploidentical stem cell transplantation (haplo-SCT) is a valid and rapidly available therapeutic option 
for patients with high-risk acute myeloid leukemia (AML) who do not have an HLA-identical sibling or 
unrelated donor.1 In recent years, most haplo-SCTs are being performed without T cell depletion (T 
cell–replete haplo-SCT) with improving outcomes due to faster immune reconstitution and a lower 
incidence of nonrelapse mortality (NRM) related to graft-versus-host disease (GVHD), graft rejection, 
and life-threatening infections.2,3 Notably, the results of haplo-SCT also improved in patients with AML 
who were ≥60 years of age.4,5 
The optimal conditioning intensity regimen for allogeneic transplantation for patients with AML is a 
debated    topic. Reduced-intensity conditioning (RIC), which is based mainly on the graft-versus-
leukemia effect and less on      the cytotoxicity of the chemotherapy or radiotherapy was originally 
developed for older and less-fit patients, those     with comorbidities, and those unable to undergo 
myeloablative conditioning (MAC).6-8 Indeed, RIC resulted in a 
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significant reduction in organ toxicity and NRM and is now widely used, even in patients who are eligible 
for MAC.9 Different groups have investigated the influence of the conditioning intensity on outcomes of 
allo-SCT from matched related or unrelated donors.10-13 Overall, MAC is associated with a  good  
antileukemic  effect  and therefore fewer relapses but with increased NRM, whereas RIC could result in 
higher relapse incidence (RI) but reduced NRM, and both approaches have similar leukemia-free 
survival (LFS) and overall survival (OS).14 The similar net outcome is despite the fact that RIC was 
generally applied to older patients and those with comor- bidities.8 Recent randomized clinical trial 
showed that age-adapted strategy could be considered in the choice of conditioning.12,15,16 
In the haplo setting, the broad HLA mismatch 
could theoretically increase the risk of immunological complications, such as acute GVHD (aGVHD) 
and chronic GVHD (cGVHD) and  graft rejection  leading to an increase in NRM.3 For this reason,  the 
intensity of conditioning, especially in different age subgroups, could have an important influence on 
outcomes and may be even more imperative and subtle than HLA- matched sibling  and  unrelated  
donor  transplants.17 The majority of studies addressing conditioning intensity in the setting of haplo-
SCT have focused on the feasibility of RIC regimens using posttransplanta- tion cyclophosphamide 
(PT-Cy) as a GVHD prophy- laxis.18-21 In these studies, relapse remains the major cause of treatment 
failure, despite the low GVHD. In contrast, MAC has been studied for both PT-Cy and other GVHD 
prophylaxes, including anti-thymocyte globulin (ATG).22-25 To date, the choice of the condi- tioning 
intensity for haplo-SCT in AML depends on patient and disease characteristics and transplantation 
center experience, but there are no clear indications. There are very few  data  comparing  MAC  and  
RIC in adult patients with AML transplanted with hap- lo-SCT.26,27 The aim of our study was to 
evaluate the impact of conditioning regimens on the outcomes of adult AML patients ≥45 years of age 
who  underwent  T cell–replete haplo-SCT. 
 
METHODS 
Study Design and Definition 
This was a retrospective registry-based analysis on behalf of the Acute  Leukemia  Working  Party 
(ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). The EBMT is a 
  
nonprofit scientific society representing more than 600 transplantation centers, mainly in Europe, 
that are required to report all consecutive stem cell transplanta- tions and follow-ups once a year. 
Data are entered, man- aged, andmaintainedinacentralonlinedatabaseinwhich each EBMT center is 
represented. For original data, the database is available at the ALWP-EBMT, Saint Antoine Hospital, 
Paris, France. Audits are routinely performed to determine the accuracy of the data. Patients or 
legal guardians provide informed consent to authorize the use of their personal information for 
research purposes. The study was approved by the ALWP institutional review board. 
Eligibility criteria for the study included all 
patients ≥45 years of age with AML who underwent a haplo-SCT (as first transplantation) between 
January 2007 and December 2016, using either PT-Cy or ATG as a GVHD prophylaxis. 
Transplantations were performed in 162 EBMT centers. 
MAC was defined as a regimen containing either total body irradiation with a dose >6 Gy, a total 
dose of oral busulfan >8 mg/kg, or a total dose of intravenous busulfan >6.4 mg/kg. All other regimens 
were defined  as RIC.28 Cytogenetics abnormalities were classified by cytogenetic status according to 
UK Medical Research Council criteria.29 
Endpoints 
The primary endpoint was LFS. Secondary endpoints were OS; refined GVHD-free, relapse-free 
survival (GRFS)30; neutrophil engraftment; aGVHD and cGVHD; RI; and NRM. LFS was defined as 
the interval from haplo-SCT to either relapse or death in remission. OS was defined as the time to 
death from all causes. GRFS events have been defined as stage III-IV aGVHD, severe cGVHD, 
disease relapse, or death from any cause after SCT.30  Engraftment was defined as the first of    3 
consecutive days with an absolute neutrophil count 
>0.5 × 109/L.  aGVHD  was  graded  according  to  the 
modified Glucksberg criteria31 and cGVHD according to the revised Seattle criteria.32 
Statistical Analysis 
Follow-up was calculated using the reverse Kaplan- Meier method. Patient-, disease-, and 
transplant-related variables were compared between the 2 groups (MAC or RIC) using the chi-
square statistic for categorical variables and the Mann-Whitney test for continuous variables. 
Cumulative incidence (CI) of relapse and NRM was calculated from the date of transplantation 
  
 
to the date of relapse or death in remission, respectively, with the other event being the competing 
risk. For studying GVHD, both relapse and death were con- sidered as competing events. 
Univariate comparisons of time-dependent endpoints were done using the log- rank  test  for  OS  
and  LFS  and  GRFS  and  the  Gray ’s test for cumulative incidence functions. A Cox propor- tional 
hazards model was used for multivariate regres- sion. All variables differing significantly between 
the 2 groups or factors known to influence outcomes were included in the Cox model. In order to 
test for a center effect, we introduced a random effect or frailty for each center into the model.33,34 
We used propensity scores (PS) weighting to 
control for pretreatment imbalances on observed vari- ables.35 The following factors were included 
in the propensity score model: patient age, disease status at transplantation, secondary versus de 
novo AML, cy- togenetics, female donor to male recipient versus other combinations, Karnofsky 
performance status less or more than 90%, previous autograft, stem cell source, patient and 
donor CMV serology, and PT-Cy versus others. The weights equal the ratio of the propensity 
score to 1 minus the propensity score in the 2 groups. Results are expressed as the hazard ratio 
(HR) with the 95% confidence interval (95% CI). All tests were 2-sided. The type 1 error rate was 
fixed at 0.05 for determination of factors associated with time to event. Analyses were performed 
using the R statistical soft- ware version 3.4.0 (R Development Core Team, Vienna, Austria); 
propensity score analysis was performed using the ipw and the npsurv packages. 
 
RESULTS 
Patients, Disease, and Transplantation Characteristics 
We analyzed 912 AML patients ≥45 years of age who underwent haplo-SCT. The conditioning 
regimens  sued were MAC (n = 373 [40.9%)] and RIC (n = 539 [59.1%]). Patients and transplantation 
characteristics are summarized in Supporting Table S1. 
For  MAC  and  RIC,  the  median  follow-up  was 
31.1 months (range, 0.5-119.9 months) and 25.7 (range, 0.43-113.8 months), respectively, and the 
median year of transplantation was 2014 and 2015, respectively. RIC recipients were older (MAC, 55.2 
years vs RIC, 61.3 years; P < .05). The majority of patients had a Karnofsky per- formance status 
(KPS) ≥90% (MAC, 71.6% vs RIC, 64.1%;  P < .05).  There were no differences in disease 
  
status at transplantation: for MAC and RIC, 48.5% versus 47.7% were in CR1, 20.1% versus 18.9% 
were in CR ≥ 2, and 31.4% versus 33.4% were in active disease, respectively (P = .79). Cytogenetic 
analysis revealed an intermediate risk in 40.8% of MAC patients and 49.2% of RIC patients, 
whereas 15.3% and 19.5% of the pa- tients undergoing MAC and RIC, respectively, harbored poor 
risk (P < .05). Secondary AML was reported in 19.1% and 24.1% of patients undergoing MAC and 
RIC, respectively (P = .07). 
The kinship of haplo-SCT donors for MAC and 
RIC was a child in 68.4% and 77.4%, respectively, and a sibling in 30.5% and 20.8%, respectively (P = 
.31). 
Details regarding transplantation characteristics, conditioning regimens, and GVHD prophylaxis are 
provided in Supporting Table S2. RIC regimens were more frequently associated with the use of 
peripheral blood as a stem cell source (MAC, 47.4% vs RIC, 60.3%; P < .05). 
The most frequent MAC conditioning regimen was TBF (thiotepa, fludarabine, busulfan) that was 
adminis- tered to 54.2% of MAC. Reduced-dose TBF was also the most frequent RIC preparative 
regimen (35.1%). Total body irradiation–based regimens were used in 6.4% and 32.2% of patients 
receiving MAC and RIC, respectively. PT-Cy–based GVHD prophylaxis was used in 78% 
of patients undergoing RIC and 77.9% of patients un- dergoing MAC, whereas ATG was 
administered in 16.9% and 18.4% of patients undergoing MAC and RIC, respectively (P = .53). The 
combination of both PT-Cy and ATG regimens was used in 5.1% and 3.7% of patients receiving 
MAC and RIC, respectively. 
Engraftment and aGVHD/cGVHD 
Neutrophil engraftment was achieved in 91% of haplo-SCTs following MAC and in 92% of 
transplanta- tions following RIC (P = .49). At 100 days, the CI for aGVHD stage II-IV was 24.8% 
versus 32.4% (P < .05), whereas the CI for stage III-IV aGVHD was 8.3% ver- sus 10.5% for MAC 
and RIC, respectively (P = .29). At 2 years, the CI for cGVHD was 27.4 versus 26.8% (P = .83) and 
the CI for extensive cGVHD was 11% ver- sus 15.1% (P = .13) for MAC and RIC, respectively. The 
propensity score analysis did not show differences in acute and cGVHD between the 2 groups 
(Supporting Table S3). In multivariate analysis (Supporting Table S4), 
the  conditioning  regimen  did  not  influence  the risk 
of  grade  2-4  and  3-4  aGVHD  (HR,  0.80;  95% CI, 
0.59-1.09, P = .14; HR, 0.81; 95% CI, 0.49-1.35, P = .41 
for MAC vs RIC, respectively) or cGVHD (HR, 0.79; 95%  CI,  0.56-1.11;  P = .17).  The  risk  of  stage 
II-IV 
  
 
 
 
Figure 1.  Probability  of  relapse  incidence  (A)  and  nonrelapse  mortality  (NRM)  (B)  after  myeloablative  conditioning  (MAC) 
or reduced-intensity conditioning (RIC)  haploidentical stem  cell  transplantation  in  acute  myeloid  leukemia  patients  ≥45  years 
of age. 
 
 
aGVHD was higher with mobilized peripheral blood as a stem cell source (HR, 1.83; 95% CI, 1.35-
2.47; P < .05) and in patients who underwent transplantation while in CR ≥ 2 (HR, 1.69; 95% CI, 
1.18-2.42; P < .05). 
Furthermore, the use of PT-Cy versus ATG (HR, 0.56; 95% CI, 0.33-0.93; P < .05) was 
associated with a reduced risk of stage III-IV aGVHD. In addition, patients with a KPS ≥90 had a 
reduced risk of cGVHD (HR, 0.69; 95% CI, 0.49-0.99; P < .05). 
Relapse Incidence and NRM 
At 2 years, the CI of relapse after haplo-SCT differed little between MAC and RIC (25.1% vs 28.7%, 
respec- tively; P = .20) (Fig. 1A). This was confirmed also by multivariate analysis (Supporting Table S4), 
no differ- ence in RI according to the conditioning intensity was observed (HR, 0.85; 95% CI, 0.62-1.16; P 
= .29). 
Factors independently associated with increased risk of relapse were disease status at 
transplantation (HR, 2.81; 95% CI, 2.06-3.83; P < .05) and poor cytogenetics 
risk (HR, 1.44; 95% CI, 1.04-2.00; P < .05). 
The CI of NRM at 2 years was 31% for MAC versus 30.3% for RIC (P = .56) (Fig. 1B). 
The most common causes of death were infection (MAC, 37.8% vs RIC, 36.1%), disease recurrence 
(MAC, 31.6%   vs  RIC,  35.4%),   and  GVHD  (MAC,  15.2% vs 
RIC, 15.1%) (Supporting Table S5). On multivariate analysis, NRM was not statistically different 
between the 2 groups (HR, 1.23; 95% CI, 0.93-1.67; P = .16). 
  
Increased age (at 10-year intervals) was associated with increased risk of NRM (HR, 1.27; 95% CI, 
1.04-1.55;  P < .05).  In addition, a KPS ≥90 (HR, 0.56;  95%  CI, 
0.42-0.75; P < .05) and the use of PT-Cy as GVHD prophylaxis  (HR,  0.69;  95%  CI,  0.48-0.99;  P < 
.05) 
were independently associated with reduced  mortality risk (Supporting Table S4). 
OS, LFS, and GRFS 
At 2 years, OS was 48.3% versus  44.1%  (P = .49),  LFS 
was 43.9% versus 41.0% (P = .63), and GRFS was 39.1% versus 33.7% (P = .17) for MAC and RIC, 
respectively (Fig. 2). On multivariate analysis (Supporting Table S4), OS, LFS, and GRFS did not 
differ between MAC and RIC. Advanced disease status at transplantation was allocated as the 
main factor associated with poor LFS (HR, 1.88; 95% CI, 1.51-2.35;  P < .05), OS (HR,  1.81; 
95% CI, 1.45-2.28, P < .05), and GRFS (HR, 1.77; 95% 
CI, 1.44-2.18, P < .05). 
KPS ≥90 (HR, 0.66; 95% CI, 0.53-0.81, P < .05; 
HR,  0.63;  95%  CI,  0.51-0.79,   P < .05; HR,  0.69; 
95% CI, 0.57-0.84, P < .05) and the use of PT-Cy for GVHD  prophylaxis  (HR,  0.74;  95%  CI, 
0.56-0.97, 
P < .05; HR, 0.75; 95% CI, 0.57-0.99, P < .05; HR, 
0.77; 95% CI, 0.60-0.99, P < .05) were the prognos- tic factors independently associated with 
higher LFS, OS, and GRFS, respectively. Overall, these results were confirmed in the propensity 
score analysis (Supporting Table S3). 
  
 
 
 
Figure 2. Probability of overall survival (A), leukemia-free survival (B), and graft-versus-host disease–free, relapse-free 
survival (GRFS) (C), after myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC) haploidentical stem cell 
transplantation in acute myeloid leukemia patients ≥45 years of age. 
 
 
 
Analysis of Outcomes According to Age 
Stratification 
With the aim to analyze the effect of 
conditioning intensity  according  to  patients’  
age,  we  performed  a subgroup analysis for 
outcomes. Age was categorized in 3 
subgroups: 45-55 years, 55-60 years, >60 
years. Of note, the intensity of the conditioning 
being MAC or RIC had no effect on 
transplantation outcome (Supporting Table 
S6). 
 
DISCUSSION 
Our study focused on adult patients with AML 
who underwent haplo-SCT between 2007 and 
2016 with 
  
the aim of identifying how conditioning intensity may influence outcomes. We analyzed a homogenous 
popula- tion in terms of disease, patient characteristics, and trans- plantation characteristics. Our results 
showed no impact of the regimen intensity, with no significant differences  in the incidence of  aGVHD,  
cGVHD,  RI,  NRM,  or  in LFS, OS, and GRFS following MAC or RIC in the haplo-SCT setting. These 
findings were also confirmed  in matched paired analysis. 
In a previous survey on behalf of the ALWP of EBMT, Rubio et al26 studied the impact of 
condition- ing intensity in a small cohort of patients with both ALL and AML who had been treated with 
heterogeneous
  
pretransplantation preparative regimens between 2001 and 2012 and observed no differences 
between MAC and RIC. The main limitation of our previous study is that the RIC group included 
young patients (range, 18-76 years) even though RIC is more applicable for patients ≥45 years of 
age. Our current study focused on a larger group of patients ≥45 years of age with AML who 
underwent transplantation in more recent years. Moreover, we also stratified the patient population 
by 3 different age subgroups (45-55  years, 55-60  years, 
>60  years)  to  analyze  whether  patients  at   different 
ages would benefit from different conditioning inten- sity regimens, hypothesizing that younger 
patients may benefit from MAC, whereas older patients may have better outcomes with RIC. Our 
current results showed no differences in the outcomes of haplo-SCT follow- ing MAC versus RIC 
according to age stratification. These results are in agreement with previous studies analyzing the 
impact of age and conditioning intensity in matched related or unrelated SCT.16,36 
Huselton et al27 recently published a propensity score analysis of conditioning intensity in peripheral 
blood haplo-SCT with PT-Cy. The study included 61 patients receiving MAC and 87 receiving RIC, with a 
median follow-up of 20.3 and 8.2 months, respectively. Patients were transplanted for different 
hematological malignancies (95  patients were transplanted for AML: 45 in the MAC and 50 in the RIC 
groups). In line with our findings, survival outcomes (OS, LFS) and aGVHD and cGVHD were not 
significantly different between the 2 groups. Furthermore, they showed a significant reduc- tion of RI and 
increased NRM with MAC. 
In our study, the most representative condition- 
ing regimen was TBF, followed by BF (busulphan and fludarabine) both in MAC and RIC (Supporting 
Table S2). We recently published a study reporting the out- comes of TBF versus BF in AML patients 
undergoing to matched related or unrelated transplantation both in the MAC and RIC setting37; our 
results showed similar sur- vival outcomes despite an increased NRM and reduced RI with TBF, but 
these results need to be confirmed in prospective clinical trials. 
In our analysis, the main factors associated with outcomes were performance status and 
disease status at transplantation. In particular, a KPS ≥90% was asso- ciated with better LFS, OS, 
and GRFS and a reduced risk of cGVHD and NRM. Disease status (active disease versus CR1) had 
a significant impacted on RI, LFS, OS, and GRFS. The risk of RI correlates with the cytogenetic 
category. Finally, higher age correlated with increased 
risk of NRM. These results highlight the importance  of the early referral of patients with AML with 
indica- tion for transplantation to haplo-SCT and the need for transplantation as soon as possible 
once first complete remission is achieved. 
Another factor associated with reduced mortality and better LFS, OS, and GRFS was the use of 
PT-Cy as the main GVHD 
prophylaxis. In vivo TCD is a known risk factor associated with high incidence of infection and 
NRM, as reported also in the unrelated donor setting.38 Moreover, a very favorable toxicity profile of 
PT-Cy Haplo-SCT has been observed, also in older patients.39 
  
Our group40 recently compared the outcomes of PT-Cy–based versus ATG-based GVHD 
prophylaxis in the haplo-SCT setting, showing improved LFS and GRFS with PT-Cy; however, 
prospective randomized studies focusing on the best platform of GVHD prophy- laxis for 
unmanipulated haplo-SCT are lacking. 
Another important finding of our current study is 
the comparable survival with the use of peripheral blood as a stem cell source compared with bone 
marrow, despite an increase risk of grade 2-4 aGVHD. These data are in agreement with recent 
reports by Ruggeri et al41 and Bashey et al42 that focused on the role of stem cell source in the haplo 
setting using PT-Cy. Importantly, our study revealed a strong center effect influencing NRM, OS, 
and LFS. In previous reports from our group, the center effect was demonstrated in the T cell–
depleted setting as well,43 and more recently in unmanipulated haplo.44 It is conceivable that the 
observed center effect is due to differences in management of posttransplantation complications, 
life-threating infections, and relapse between the various centers. 
In  conclusion,  while in  the matched related or 
unrelated transplant setting, data from prospective  trials showed higher NRM after MAC counterbal- 
anced by higher RI after RIC with similar survival outcomes,12,13,16 our results in the haplo setting 
showed  no differences in outcomes. These results are important for transplant physicians to keep in 
mind when choos- ing the appropriate regimen for the patients according  to disease risk features, 
comorbidities, and transplan- tation characteristics. Although our study has some limitations due to its 
retrospective nature—namely, the theoretic possibility of patient selection, the unavail- ability of the 
Sorror score in the EBMT registry, and some missing data (mainly of molecular markers)—we were 
able to demonstrate that  both  MAC  and  RIC  are  suitable  preparative  regimens  for  AML  
patients 
≥45  years of  age who  undergo haplo-SCT.  The use of 
  
 
RIC may offer the possibility of lowering early 
toxicity and enhance posttransplantation 
maintenance therapy to prevent relapse in this 
high-risk setting. Finally, the optimal regimen 
and GVHD prophylaxis should be chosen 
according to patient and disease characteris- 
tics. Our study may serve as the background for 
a well- designed prospective clinical trial to 
investigate the best conditioning intensity 
platform in AML patients 
≥45 years of age who undergo haplo-SCT. 
 
REFERENCES 
1. Passweg JR, Baldomero H, Bader P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 
European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018;53:1139-1148. 
2. Chang Y-J, Huang X-J. Improving the clinical outcome of unma- nipulated haploidentical blood and marrow transplantation. Bone 
Marrow Transplant. 2015;50(suppl 2):S21-S23. 
3. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA- haploidentical blood or marrow transplantation. Nat Rev Clin 
Oncol. 2016;13:10-24. 
4. Santoro N, Labopin M, Giannotti F, et al. Unmanipulated haploiden- tical in comparison to matched unrelated donor stem cell 
transplan- tation in patients 60 years and older with acute myeloid leukemia:  a comparative study on behalf of the ALWP of the 
EBMT. J Hematol Oncol. 2018;11:55. 
5. Muffly L, Pasquini MC, Martens M, et al. Increasing use of alloge- neic hematopoietic cell transplantation in patients aged 70 
years and older in the United States. Blood. 2017;130:1156-1164. 
6. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hema- topoietic progenitor cells with purine analog-containing 
chemother- apy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536. 
7. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmye- loablative allogeneic transplantation: clinical outcomes and 
immune reconstitution. J Clin Oncol. 2007;25:690-697. 
8. Savani BN, Labopin M, Kröger N, et al. Expanding transplant options to patients over 50 years. Improved outcome after 
reduced intensity conditioning mismatched-unrelated donor transplan- tation for patients with acute myeloid leukemia: a 
report from  the acute leukemia working party of the EBMT. Haematologica. 2016;101:773-780. 
9. Pasquini MC, Wang Z, Horowitz MM, Gale  RP.  2010  report  from the Center for International Blood and Marrow Transplant 
Research (CIBMTR): current uses and outcomes of hematopoietic 
  
cell transplants for blood and bone marrow disorders. Clin 
Transpl. 2010:87-105. 
10. Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, 
Mohty 
M. Reduced intensity conditioning allogeneic 
hematopoietic cell transplantation for adult acute myeloid 
leukemia in complete remis- sion—a review from the 
acute leukemia working party of the EBMT. Haematologica. 
2015;100:859-869. 
11. Luger SM, Ringdén O, Zhang MJ, et al. Similar 
outcomes using myeloablative vs reduced-intensity 
allogeneic transplant prepara- tive regimens for AML or 
MDS. Bone Marrow Transplant. 2012;47: 203-211. 
12. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative 
versus reduced-intensity hematopoietic cell 
transplantation for acute myeloid leukemia and 
myelodysplastic syndromes. J Clin Oncol. 2017;35:1154-
1161. 
13. Zeng W, Huang L, Meng F, Liu Z, Zhou J, Sun H. 
Reduced-intensity and myeloablative conditioning 
allogeneic hematopoietic stem cell transplantation in 
patients with acute myeloid leukemia and myelo- 
dysplastic syndrome: a meta-analysis and systematic 
review. Int J Clin Exp Med. 2014;7:4357-4368. 
14. Weisdorf DJ. Reduced-intensity versus myeloablative 
allogeneic transplantation. Hematol Oncol Stem Cell Ther. 
2017;10:321-326. 
15. Lioure B, Béné MC, Pigneux A, et al. Early matched 
sibling hemato- poietic cell transplantation for adult AML 
in first remission using an age-adapted strategy: long-
term results of a prospective GOELAMS study. Blood. 
2012;119:2943-2948. 
16. Bornhäuser M, Kienast J, Trenschel R, et al. Reduced-
intensity con- ditioning versus standard conditioning 
before allogeneic haemopoi- etic cell transplantation in 
patients with acute myeloid leukaemia in first complete 
remission: a prospective, open-label randomised phase 3 
trial. Lancet Oncol. 2012;13:1035-1044. 
17. Jagasia M, Arora M, Flowers MED, et al. Risk factors for 
acute GVHD and survival after hematopoietic cell 
transplantation. Blood. 2012;119:296-307. 
18. Luznik  L,  O ’Donnell  PV,  Symons  HJ,  et  al.  HLA-
haploidentical bone marrow transplantation for hematologic 
malignancies using nonmyeloablative conditioning and high-
dose, posttransplantation cyclophosphamide. Biol Blood 
Marrow Transplant. 2008;14:641-650. 
19. Munchel AT, Kasamon YL, Fuchs EJ. Treatment of 
hematological malignancies with nonmyeloablative, HLA-
haploidentical bone marrow transplantation and high 
dose, post-transplantation cyclo- phosphamide. Best Pract 
Res Clin Haematol. 2011;24:359-368. 
20. McCurdy SR, Kanakry JA, Showel MM, et al. Risk-stratified 
out- comes of nonmyeloablative HLA-haploidentical BMT 
with high-dose posttransplantation cyclophosphamide. 
Blood. 2015;125:3024-3031. 
21. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. 
Haploidentical transplant with posttransplant 
cyclophosphamide vs matched unrelated donor transplant 
for acute myeloid leukemia. Blood. 2015;126:1033-1040. 
22. Bacigalupo A, Dominietto A, Ghiso A, et al. Unmanipulated 
haploidentical bone marrow transplantation and post-
transplant cyclophosphamide for hematologic malignanices 
following a mye- loablative conditioning: an update. Bone 
Marrow Transplant. 2015;50 (suppl 2):S37-S39. 
23. Solomon SR, Sizemore CA, Sanacore M, et al. 
Haploidentical transplantation using T cell replete 
peripheral blood stem cells and myeloablative conditioning 
in patients with high-risk hematologic malignancies who 
lack conventional donors is well tolerated and pro- duces 
excellent relapse-free survival. Biol Blood Marrow Transplant. 
2012;18:1859-1866. 
24. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated 
haploidentical bone marrow transplantation and 
posttransplantation cyclophosphamide for hematologic 
malignancies after myeloablative conditioning. Biol Blood 
Marrow Transplant. 2013;19:117-122. 
25. Solomon SR, Sizemore CA, Sanacore M, et al. Total body 
irradia- tion-based myeloablative haploidentical stem cell 
transplantation is a safe and effective alternative to 
unrelated donor transplantation  in patients without 
matched sibling donors. Biol Blood Marrow Transplant. 
2015;21:1299-1307. 
  
 
26. Rubio MT, Savani BN, Labopin M, et al. Impact of 
conditioning intensity in T-replete haplo-identical stem cell 
transplantation  for  acute leukemia: a report from the acute 
leukemia working party of    the EBMT. J Hematol Oncol. 
2016;9:25. 
27. Huselton E, Slade M, Trinkaus KM, DiPersio JF, 
Westervelt P, Romee R. Propensity score analysis of 
conditioning intensity in pe- ripheral blood haploidentical 
hematopoietic cell transplantation. Biol Blood Marrow 
Transplant. 2018;24:2047-2055. 
28. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the 
intensity of conditioning regimens: working definitions. Biol 
Blood Marrow Transplant. 2009;15:1628-1633. 
29. Grimwade D, Hills RK, Moorman AV, et al. Refinement 
of cytogenetic classification in acute myeloid leukemia: 
determi- nation of prognostic significance of rare 
recurring chromosomal abnormalities among 5876 
younger  adult  patients  treated  in the United Kingdom 
Medical Research Council trials. Blood. 2010;116:354-
365. 
30. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. 
Definition  of GvHD-free, relapse-free survival for registry-
based studies: an ALWP-EBMT analysis on patients with 
AML in remission. Bone Marrow Transplant. 2016;51:610-
611. 
31. Przepiorka D, Weisdorf D, Martin P, et al. 1994 
Consensus Conference on Acute GVHD Grading. Bone 
Marrow Transplant. 1995;15:825-828. 
32. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host 
disease. 
Biol Blood Marrow Transpl. 2003;9:215-233. 
33. Hougaard P. Frailty models for survival data. Lifetime Data 
Anal. 1995;1:255-273. 
34. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects 
in multi-centre survival studies: A Monte Carlo comparison of 
fixed and random effects tests. Stat Med. 1999;18:1489-1500. 
35. Mccaffrey DF, Griffin BA, Almirall D, Slaughter ME, 
Ramchand R, Burgette LF. A tutorial on propensity score 
estimation for mul- tiple treatments using generalized 
boosted models. Stat Med. 2013;32:3388-3414. 
36. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of 
age on outcome of reduced-intensity hematopoietic cell 
transplantation 
for older patients with acute myeloid leukemia  in  first 
com- plete remission or with myelodysplastic syndrome. 
J Clin Oncol. 2010;28:1878-1887. 
37. Saraceni F, Labopin M, Hamladji RM, et al. Thiotepa-
busulfan- fludarabine compared to busulfan-fludarabine 
for sibling and unre- lated donor transplant in acute 
myeloid leukemia in first remission. Oncotarget. 
2017;9:3379-3393. 
38. Walker I, Panzarella T, Couban S, et al. Pretreatment with 
anti-thymocyte globulin versus no anti-thymocyte globulin 
in pa- tients with haematological malignancies undergoing 
haemopoietic cell transplantation from unrelated donors: a 
randomised, controlled, open-label, phase 3, multicentre 
trial. Lancet Oncol. 2016;17:164-173. 
39. Blaise D, Fürst S, Crocchiolo R, et al. Haploidentical T 
cell-replete transplantation with post-transplantation 
cyclophosphamide for pa- tients in or above the sixth 
decade of age compared with allogeneic hematopoietic 
stem cell transplantation from an human leukocyte 
antigen-matched related or unrelated donor. Biol Blood 
Marrow Transplant. 2016;22:119-124. 
40. Ruggeri A, Sun Y, Labopin M, et al. Post-transplant 
cyclophos- phamide versus antithymocyte-globulin as graft 
versus  host  dis-  ease prophylaxis in haploidentical 
transplant. Haematologica. 2017;102:401-410. 
41. Ruggeri A, Labopin M, Bacigalupo A, et al. Bone marrow 
versus mo- bilized peripheral blood stem cells in 
haploidentical transplants using posttransplantation 
cyclophosphamide. Cancer. 2018;124:1428-1437. 
42. Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized  
peripheral  blood stem cells versus unstimulated bone 
marrow as a graft source for  T-cell–replete  haploidentical  
donor  transplantation  using  post- transplant 
cyclophosphamide. J Clin Oncol. 2017;35:3002-3009. 
43. Ciceri F, Labopin M, Aversa F, et al. A survey of fully 
haploidentical hematopoietic stem cell transplantation in 
adults with high-risk acute leukemia: a risk factor analysis 
of outcomes for patients in remission at transplantation. 
Blood. 2008;112:3574-3581. 
44. Ruggeri A, Labopin M, Sanz G, et al. Comparison of 
outcomes after unrelated cord  blood  and  unmanipulated  
haploidentical stem cell transplantation in adults with 
acute leukemia. Leukemia. 2015;29:1891-1900. 
